**EXPLANATORY STATEMENT**

*Therapeutic Goods Act 1989*

*Therapeutic Goods (Standard for Psilocybine) (TGO 113) Order 2024*

The *Therapeutic Goods Act 1989* (the Act) provides for the establishment and maintenance of a national system of controls for the quality, safety, efficacy or performance, and timely availability, of therapeutic goods that are used in, or exported from, Australia. The Act is administered by the Therapeutic Goods Administration (the TGA) within the Australian Government Department of Health and Aged Care (the Department).

Subsection 10(1) of the Act provides that the Minister may, by legislative instrument, make an order determining that matters specified in the order constitute a standard for therapeutic goods or a class of therapeutic goods identified in the order. Subsection 10(2) provides that an order establishing a standard for therapeutic goods may be specified by reference to the quality of the goods, or the procedures to be carried out in the manufacture of the goods, among other matters. An order may also require that a matter relating to the standard be determined in accordance with a particular test.

Importantly, a person who imports, exports or supplies therapeutic goods that do not conform to an applicable standard may be subject to offence and civil penalty provisions in sections 14 and 14A of the Act. The Secretary may, however, give consent in writing in relation to the importation, exportation or supply of therapeutic goods that do not conform to an applicable standard, in accordance with those sections.

The *Therapeutic Goods (Standard for Psilocybine) (TGO 113) Order 2024* (the Order) is made under section 10 of the Act. The purpose of the Order is to establish a ministerial standard for plant derived psilocybine, plant derived psilocybine products, synthetic psilocybine and synthetic psilocybine products. The Order is designed to specify important minimum benchmarks to ensure the quality of such goods for Australian patients, principally by reference to labelling requirements, assay limits and specified tests for the active pharmaceutical ingredient (API) and finished product.

**Background**

The Australian Government is responsible for regulating the quality, safety, and efficacy or performance of therapeutic goods. In relation to therapeutic goods other than medical devices, this is achieved in part by requiring compliance with the default standards under the Act and with any ministerial standards made under section 10 of the Act. Such standards may relate to a range of matters including for instance the quality of the goods, procedures to be carried out in their manufacture, and requiring that matters be determined in accordance with a particular test.

Prior to 1 July 2023, psilocybine was only included in Schedule 9 (Prohibited substances) to the Poisons Standard, which limited its use to authorised research and analytical purposes only. On 3 February 2023, a delegate of the Secretary made a decision to amend the entry for psilocybine in the Poisons Standard. As a result of this scheduling decision, effective from 1 July 2023, psilocybine was added to Schedule 8 (Controlled Drugs) to the Poisons Standard, permitting its use for the treatment of treatment‑resistant depression (TRD).

The inclusion of psilocybine in Schedule 8 is subject to the additional controls imposed in relation to it under Appendix D to the Poisons Standard, which include in particular that psilocybine may only be supplied for the treatment of TRD if:

* prescribed or if its supply is authorised, by a medical practitioner who is registered under state or territory legislation that forms part of the Health Practitioner Regulation National law as a specialist psychiatrist and for whom an authority under subsection 19(5) of the Act that covers psilocybine is in force (subsection 19(5) of the Act underpins the TGA’s Authorised Prescriber pathway for accessing unapproved therapeutic goods through an authority granted to a medical practitioner, in specified circumstances); or
* for use in a clinical trial that is approved by, or notified to, the Secretary in accordance with the Act.

For all other, uses psilocybine remains covered by the entry for it in Schedule 9 to the Poisons Standard.

There are currently no products containing psilocybine that have been approved by the TGA for registration in the Australian Register of Therapeutic Goods (the Register). As such, access to psilocybine may occur solely through the pathways established in the Act for accessing unapproved therapeutic goods, through clinical trials and the Authorised Prescriber scheme. Unapproved therapeutic goods accessed through these pathways have not been evaluated by the TGA for safety, quality or efficacy.

**Purpose**

Concerns have arisen that there are currently no product standards, such as pharmacopoeial monographs, setting out quality requirements for psilocybine, whether as an API or a finished product. As such, the Order is designed to addresses these concerns by establishing a ministerial standard for plant derived psilocybine, plant derived psilocybine products, synthetic psilocybine and synthetic psilocybine products, whether imported into Australia or manufactured domestically. The Order is intended to provide an assurance to medical practitioners and patients that psilocybine medicines meet minimum quality requirements.

The Order will contribute to the quality and efficacy of plant derived psilocybine, plant derived psilocybine products, synthetic psilocybine and synthetic psilocybine products by ensuring that these goods are manufactured uniformly according to minimum standards. Standardisation is necessary to assure medical practitioners and patients that psilocybine as an API or finished product will be manufactured to a consistent and reproducible quality, which is essential to support the known safety and efficacy of any medicine.

The Order will also contribute to the quality of the psilocybine products to which it applies through requiring that the average content of psilocybine is within specified limits, and requiring that such products meet specified outcomes after undergoing a range of specified kinds of tests, for instance tests for the purity of psilocybine and tests for heavy metals and residual solvents.

**Incorporation by reference**

Subsection 10(4) of the Act relevantly provides that, despite subsection 14(2) of the *Legislation Act 2003* (the Legislation Act), an order (or a variation of an order) under this provision may make provision in relation to a matter by applying, adopting or incorporating, with or without modification, any matter contained in an instrument or other writing as in force or existing from time to time.

The following identifies and explains each of the documents that are incorporated by reference in the Order, how they may be accessed and the intended manner of incorporation.

*Pharmacopoeia*

The Order incorporates by reference the European Pharmacopoeia and the United States Pharmacopeia-National Formulary, which are default standards for the purposes of the Act. The note in section 4 of the Order makes it clear that each is defined in subsection 3(1) of the Act.

The definitions of the pharmacopoeia in subsection 3(1) of the Act refer to the publications of each as being in force from time to time. The intention in the Order is therefore to adopt the defined meaning of the European Pharmacopoeia and the United States Pharmacopeia-National Formulary as set out in subsection 3(1) of the Act. These pharmacopoeia are therefore incorporated as in force or existing from time to time, in accordance with these provisions, an approach permitted by subsection 10(4) of the Act. They may be accessed from https://pheur.edqm.eu/home and www.uspnf.com/.

While unfortunately these pharmacopoeia are not available for free, it is anticipated that persons most affected by their adoption in the Order (sponsors and manufacturers of plant derived psilocybine, plant derived psilocybine products, synthetic psilocybine and synthetic psilocybine products) would be in possession of these documents in order to import, supply or manufacture such goods. As important international benchmarks for the safety and quality of therapeutic goods, it would be infeasible from a regulatory perspective, particularly in relation to the quality of plant derived psilocybine, plant derived psilocybine products, synthetic psilocybine and synthetic psilocybine products that are not entered in the Register and that have therefore not been subject to pre-market scrutiny before being available for patients in Australia, to not adopt such benchmarks on the basis that they are not available for free.

In addition, by prior written arrangement with the TGA, members of the public may request to view the pharmacopoeia without charge at the TGA office in Fairbairn, ACT.

It should also be noted that the National Library’s Trove online system (www.trove.nla.gov.au) allows users to identify libraries in Australia that are open to the public where editions, in most cases earlier editions, of these pharmacopoeia may be viewed.

Members of the public may also approach any library that participates in inter-library loans with those libraries to request an inter-library loan, or to obtain a photocopy of a particular part or monograph for personal study or research, but not for commercial purposes. Fees may apply in relation to the making of such a request. Enquiries should be made with local libraries, State libraries or the National Library.

*ICH Q3D guideline document*

The Order also incorporates by reference the ICH Harmonised Guideline: *Guideline for Elemental Impurities Q3D* (the ICH Q3D guideline document), developed by the International Council for Harmonisation of Technical requirements for Pharmaceuticals for Human Use.

The ICH Q3D guideline document sets out processes to assess and control elemental impurities in new drug products and new drug products containing existing substances, including by establishing a Permitted Daily Exposure for each element of toxicological concern.

The ICH Q3D guideline document is incorporated as in force from time to time, in accordance with subsection 10(4) of the Act. The ICH Q3D guideline document is available for free from the ICH website at www.ich.org/.

**Consultation**

Between 8 December 2023 and 31 January 2024, the TGA undertook public consultation in relation to the development of the Order, including releasing a draft version of the Order, to seek comments on the appropriateness of the proposed technical requirements specified in the draft Order. 25 submissions were received from various stakeholders including sponsors, manufacturers, industry organisations, health care practitioners, pharmacists, patients and members of the public.

The consultation confirmed there was broad in-principle support for the Order. Some submissions suggested additional tests or tightening of some assay limits, or to employ USP or ICH guidelines as alternatives to European pharmacopeial methods and limits or sought further clarity on the requirements. Some submissions expressed concern about capacity to comply with the Order once in place, and proposed the inclusion of transitional arrangements. These suggestions were considered carefully, and a number were reflected in the final Order, including in particular that the Order commences on 6 January 2025 to allow time for stakeholders to prepare to comply.

**Other details**

Details of the Order are set out in **Attachment A.**

The Order is compatible with the human rights and freedoms recognised or declared under section 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*. A full statement of compatibility is set out in **Attachment B**.

The Order is a disallowable legislative instrument for the purposes of the Legislation Act, and commences on 6 January 2025.

The Office of Impact Analysis advised that an Impact Analysis was not required in relation to the making of the Order, as the making of the Order is unlikely to have a more than minor regulatory impact (OIA23-05637).

The TGA published a technical barrier to trade notification (G/TBT/N/AUS/165, Attachment C) on the World Trade Organization’s (WTO) notification platform in relation to the Order. The period for response was from 18 December 2023 to 31 January 2024, and no submissions were received from WTO Members.

**Attachment A**

**Details of the *Therapeutic Goods (Standard for Psilocybine) (TGO 113) Order 2024***

**Part 1—Preliminary**

This Part provides for the name of the *Therapeutic Goods (Standard for Psilocybine) (TGO 113) Order 2024* (the Order), its commencement, authority and application, the therapeutic goods for which the Order constitutes a standard, and definitions for key terms used in the Order.

**Section 1 – Name**

This section provides that the name of the Order is the *Therapeutic Goods (Standard for Psilocybine) (TGO 113) Order 2024*, and that the Order may also be cited as TGO 113.

**Section 2 – Commencement**

This section provides that the Order commences on 6 January 2025.

Commencement in January 2025 is intended to provide sufficient time for manufacturers and sponsors to ensure their goods comply with the requirements introduced by the Order.

**Section 3 – Authority**

This section provides that the legislative authority for making the Order is section 10 of the *Therapeutic Goods Act 1989* (the Act).

Subsection 10(1) of the Act provides that the Minister may, by legislative instrument, make an order determining that matters specified in the order constitute a standard for therapeutic goods or a class of therapeutic goods identified in the order.

**Section 4 – Definitions**

This section provides the definitions of key terms used in the Order, including, ‘active ingredient’, ‘batch number’, ‘capsule’, ‘ICH Q3D guideline document’, ‘manufacturing licence’, ‘psilocin’ ‘psilocybine’ and ‘tryptamines’.

This section also notes that a number of terms used in the Order, including ‘batch’, ‘container’, ‘European Pharmacopoeia’, ‘label’, ‘manufacture’, ‘sponsor’, ‘standard’, and ‘United States Pharmacopeia-National Formulary’ are defined in subsection 3(1) of the Act, and therefore have the same meaning as in the Act.

**Section 5 – Standard**

This section provides that matters specified in the Order constitute a standard for plant derived psilocybine, plant derived psilocybine products, synthetic psilocybine and synthetic psilocybine products.

**Section 6 – Application**

This section specifies the goods to which the Order does and does not apply.

Subsection 6(1) provides that, subject to subsection (2) the Order applies to:

* plant derived psilocybine;
* plant derived psilocybine products;
* synthetic psilocybine; and
* synthetic psilocybine products.

Subsection 6(2) provides that the Order does not apply to:

* Therapeutic goods that are the subject of an approval under paragraph 19(1)(b) of the Act (this provision underpins the importation and supply of unapproved therapeutic goods for use in clinical trials that are required to be approved to the Secretary); or
* therapeutic goods mentioned in item 1 of Schedule 5 to the *Therapeutic Goods Regulations 1990* (the Regulations) (this item underpins the TGA’s personal importation scheme, under which a person may lawfully import an unapproved therapeutic good for their personal use or the use of a member of their immediate family, subject to specified limitations); or
* therapeutic goods mentioned in items, 3, 4, 8, 10, 11 or 12 of Schedule 5A to the Regulations, subject to compliance with the conditions specified in those items (these items exempt therapeutic goods from the requirement to be registered or listed in the Register in specified circumstances, including for instance for use in a clinical trial that is required to be notified to the Secretary, or where the goods are imported by particular persons or are part of particular medical supplies of a visiting ship or aircraft).

**Part 2—Requirements for plant derived psilocybine**

This Part specifies requirements for plant derived psilocybine in the form of an active pharmaceutical ingredient (API).

**Section 7 – Application of this part**

This section provides that this Part applies to plant derived psilocybine.

**Section 8 – Assay limits**

Subsection 8(1) specifies the assay limits that apply to the purity of psilocybine, psilocin and tryptamines in psilocybin extract, calculated on a dried basis.

Subsection 8(2) specifies the assay limits that apply to the purity of psilocybine and psilocin in psilocybine isolate, calculated on a dried basis.

**Section 9 – Identification**

This section specifies that the psilocybine mushroom used in the manufacture of psilocybine extract or psilocybine isolate must be able to be positively identified through macroscopic examination, microscopic examination and chromatographic procedures.

These methods must be performed conjunctively rather than disjunctively. The purpose of this section is to ensure that the mushroom used in the manufacture of psilocybine extract or psilocybine isolate is the species *Psilocybe cubensis*.

**Section 10 – Tests**

This section provides that for each item in the table in Parts 1 and 2 of Schedule 1, plant derived psilocybine must comply with the requirements specified in column 4 using the test method specified in column 3, in relation to the test specified in column 2.

**Part 3—Requirements for plant derived psilocybine products**

This Part specifies requirements for plant derived psilocybine in the form of a finished product.

**Section 11 – Application of this part**

This section provides that this Part applies to plant derived psilocybine products.

**Section 12 – General**

Subsection 12 (1) provides that the psilocybine extract or psilocybine isolate used in the manufacture of plant derived psilocybin products must be obtained from the psilocybine mushroom.

Subsection 12(2) provides that psilocybine extract products must contain psilocybine extract as the only active ingredient and be manufactured in the dosage form of a capsule for oral administration.

Subsection 12(3) provides that psilocybine isolate products must contain psilocybine isolate as the only active ingredient and be manufactured in the dosage form of a capsule for oral administration.

**Section 13 – Assay limits**

Subsection 13(1) specifies the average specified range of concentration of psilocybine, psilocin and tryptamines for psilocybine extract products in a pooled sample of a minimum of 20 capsules.

Subsection 13(2) specifies the average specified range of concentration of psilocybine for psilocybine isolate products in a pooled sample of a minimum of 20 capsules.

**Section 14 – Tests**

Subsection 14(1) provides that, subject to subsection (2), for each item in the table in Part 1 of Schedule 2, a psilocybine extract product must comply with the requirements specified in column 4 using the test method specified in column 3, in relation to the test specified in column 2.

Subsection 14(2) sets out an exemption to the above requirement for an extemporaneously compounded psilocybine extract product that complies with the conditions specified in paragraphs 14(2)(a) and (b).

Subsection 14(3) provides that, subject to subsection (4), for each item in the table in Part 2 of Schedule 2, a psilocybine isolate product must comply with the requirements specified in column 4 using the test method specified in column 3, in relation to the test specified in column 2.

Subsection 14(4) sets out an exemption to the above requirement for an extemporaneously compounded psilocybine isolate product that complies with the conditions specified in paragraphs 14(4)(a) and (b).

**Part 4—Requirements for synthetic psilocybine**

This Part specifies requirements for synthetic psilocybine in the form of an API.

**Section 15 – Application of this part**

This section provides that this Part applies to synthetic psilocybine.

**Section 16 – Assay limits**

This section specifies the assay limits that apply to the purity of psilocybine and psilocin in synthetic psilocybin.

**Section 17 – Tests**

This section provides that for each item in the table in Schedule 3, synthetic psilocybine must comply with the requirements specified in column 4 using the test method specified in column 3, in relation to the test specified in column 2.

**Part 5—Requirements for synthetic psilocybine products**

This Part specifies requirements for synthetic psilocybine in the form of a finished product.

**Section 18 – Application of this part**

This section provides that this Part applies to synthetic psilocybine products.

**Section 19 – General**

This section provides that synthetic psilocybine product must contain synthetic psilocybine as the only active ingredient and be manufactured in the dosage form of a capsule for oral administration.

**Section 20 – Assay limits**

This section specifies the average range of concentration of synthetic psilocybine for synthetic psilocybine products in a pooled sample of a minimum of 20 capsules.

**Section 21 – Elemental impurities**

This section specifies that synthetic psilocybine products must comply with the requirements for elemental impurities specified in the ICH Q3D guideline document.

**Section 22 – Tests**

Subsection 15(1) provides that, subject to subsection (2), for each item in the table in Schedule 4, a synthetic psilocybine product must comply with the requirements specified in column 4 using the test method specified in column 3, in relation to the test specified in column 2.

Subsection 15(2) sets out an exemption to the above requirement for an extemporaneously compounded synthetic psilocybine product that complies with the conditions specified in paragraphs 22(2)(a) and (b).

**Part 6—Labelling requirements**

This Part specifies labelling requirements that apply in relation to psilocybine products.

**Section 23 – Application of this part**

This section provides that this Part applies to psilocybine products.

**Section 24 – Information to be included on the label**

Subsection 24(1) provides that the label of a psilocybine product, other than a psilocybine product that has been extemporaneously compounded, must contain all of the information specified in paragraphs 24(1)(a)-(k).

Subsection 24(2) specifies that all of the information required to be included on the label of a psilocybine product must be in English and must be legible, clearly visible and not obscured, and durable.

**Schedule 1 – Specified tests for plant derived psilocybine**

Schedule 1 specifies the tests, test methods and requirements that apply to plant derived psilocybine. In particular:

* Part 1 specifies tests, test methods and requirements that apply to psilocybine extract; and
* Part 2 specifies tests, test methods and requirements that apply to psilocybine isolate.

**Schedule 2 – Specified tests for plant derived psilocybine products**

Schedule 2 specifies the tests, test methods and requirements that apply to plant derived psilocybine products. In particular:

* Part 1 specifies tests, test methods and requirements that apply to psilocybine extract products; and
* Part 2 specifies tests, test methods and requirements that apply to psilocybine isolate products.

**Schedule 3 – Specified tests for synthetic psilocybine**

Schedule 3 specifies the tests, test methods and requirements that apply to synthetic psilocybine.

**Schedule 4 – Specified tests for synthetic psilocybine products**

Schedule 4 specifies the tests, test methods and requirements that apply to synthetic psilocybine products.

**Attachment B**

**Statement of Compatibility with Human Rights**

Prepared in accordance with Part 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*

*Therapeutic Goods (Standard for Psilocybine) (TGO 113) Order 2024*

This disallowable legislative instrumentis compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*.

**Overview of legislative instrument**

Subsection 10(1) of the Act provides that the Minister may, by legislative instrument, make an order determining that matters specified in the order constitute a standard for therapeutic goods or a class of therapeutic goods identified in the order. Subsection 10(2) provides that an order establishing a standard for therapeutic goods may be specified by reference to the quality of the goods, or the procedures to be carried out in the manufacture of the goods, among other matters. An order may also require that a matter relating to the standard be determined in accordance with a particular test.

Importantly, a person who imports, exports or supplies therapeutic goods that do not conform to an applicable standard may be subject to offence and civil penalty provisions in sections 14 and 14A of the Act. The Secretary may, however, give consent in writing in relation to the importation, exportation or supply of therapeutic goods that do not conform to an applicable standard, in accordance with those sections.

The *Therapeutic Goods (Standard for Psilocybine) (TGO 113) Order 2024* (the Order) is made under section 10 of the Act. The purpose of the Order is to establish a ministerial standard for plant derived psilocybine, plant derived psilocybine products, synthetic psilocybine and synthetic psilocybine products. The Order is designed to specify important minimum benchmarks to ensure the quality of such goods for Australian patients, principally by reference to labelling requirements, assay limits and specified tests for the active pharmaceutical ingredient (API) and finished product.

**Background**

The Australian Government is responsible for regulating the quality, safety, and efficacy or performance of therapeutic goods. In relation to therapeutic goods other than medical devices, this is achieved in part by requiring compliance with the default standards under the Act and with any ministerial standards made under section 10 of the Act. Such standards may relate to a range of matters including for instance the quality of the goods, procedures to be carried out in their manufacture, and requiring that matters be determined in accordance with a particular test.

Prior to 1 July 2023, psilocybine was only included in Schedule 9 (Prohibited substances) to the Poisons Standard, which limited its use to authorised research and analytical purposes only. On 3 February 2023, a delegate of the Secretary made a decision to amend the entry for psilocybine in the Poisons Standard. As a result of this scheduling decision, effective from 1 July 2023, psilocybine was added to Schedule 8 (Controlled Drugs) to the Poisons Standard, permitting its use for the treatment of treatment‑resistant depression (TRD).

The inclusion of psilocybine in Schedule 8 is subject to the additional controls imposed in relation to it under Appendix D to the Poisons Standard, which include in particular, that psilocybine may only be supplied for the treatment of TRD if:

* prescribed or if its supply is authorised, by a medical practitioner who is registered under state or territory legislation that forms part of the Health Practitioner Regulation National law as a specialist psychiatrist and for whom an authority under subsection 19(5) of the Act that covers psilocybine is in force (subsection 19(5) of the Act underpins the TGA’s Authorised Prescriber pathway for accessing unapproved therapeutic goods through an authority granted to a medical practitioner, in specified circumstances); or
* for use in a clinical trial that is approved by, or notified to, the Secretary in accordance with the Act.

For all other, uses psilocybine remains covered by the entry for it in Schedule 9 to the Poisons Standard.

There are currently no products containing psilocybine that have been approved by the TGA for registration in the Australian Register of Therapeutic Goods (the Register). As such, access to psilocybine may occur solely through the pathways established in the Act for accessing unapproved therapeutic goods, through clinical trials and the Authorised Prescriber scheme. Unapproved therapeutic goods accessed through these pathways have not been evaluated by the TGA for safety, quality or efficacy.

**Purpose**

Concerns have arisen that there are currently no product standards, such as pharmacopoeial monographs, setting out quality requirements for psilocybine, whether as an API or a finished product. As such, the Order is designed to addresses these concerns by establishing a ministerial standard for plant derived psilocybine, plant derived psilocybine products, synthetic psilocybine and synthetic psilocybine products, whether imported into Australia or manufactured domestically. The Order is intended to provide an assurance to medical practitioners and patients that psilocybine medicines meet minimum quality requirements.

The Order will contribute to the quality and efficacy of plant derived psilocybine, plant derived psilocybine products, synthetic psilocybine and synthetic psilocybine products by ensuring that these goods are manufactured uniformly according to minimum standards. Standardisation is necessary to assure medical practitioners and patients that psilocybine as an API or finished products will be manufactured to a consistent and reproducible quality, which is essential to support the known safety and efficacy of any medicine. The Order will also contribute to the quality of the psilocybine products to which it applies through requiring that the average content of psilocybine is within specified limits, and requiring that such products meet specified outcomes after undergoing a range of specified kinds of tests, for instance tests for the purity of psilocybine and tests for heavy metals and residual solvents.

**Human rights implications**

The instrument engages the right to health in Article 12 of the International Covenant on Economic, Social and Cultural Rights (the ICESCR). Article 12 of the ICESCR promotes the right of all individuals to enjoy the highest attainable standards of physical and mental health.

In *General Comment No.14: The Right to the Highest Attainable Standard of Health (Art.12)* (2000), the United Nations Committee on Economic, Social and Cultural Rights states that health is a ‘fundamental human right indispensable for the exercise of other human rights’, and that the right to health is not be understood as the right to be healthy, but includes the right to a system of health protection which provides equal opportunity for people to enjoy the highest attainable level of health.

The Order takes positive steps to promote the right to health by helping to ensure the quality of psilocybine products supplied in Australia. The Order does this through specifying the procedures to be carried out in the manufacture of the psilocybine products to which the Order applies, and through specifying testing limits for both psilocybine active pharmaceutical ingredients (API) and finished products.

The introduction of a minimum standard for psilocybine is particularly important as psilocybine products that are available for supply in Australia are not included in the Register and, as such, have not been subjected to a process of pre-market scrutiny before being made available to Australian patients.

**Conclusion**

The Order is compatible with human rights because it maintains and supports the right to health in Article 12 of the ICESCR and otherwise does not raise any other human rights issues.